This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Hypertension  • Randomized Controlled Trial  • Lipids and Lipid Disorders  • Alert me on articles by topic

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group

JAMA. 2002;288:2998-3007.

Context  Studies have demonstrated that statins administered to individuals with risk factors for coronary heart disease (CHD) reduce CHD events. However, many of these studies were too small to assess all-cause mortality or outcomes in important subgroups.

Objective  To determine whether pravastatin compared with usual care reduces all-cause mortality in older, moderately hypercholesterolemic, hypertensive participants with at least 1 additional CHD risk factor.

Design and Setting  Multicenter (513 primarily community-based North American clinical centers), randomized, nonblinded trial conducted from 1994 through March 2002 in a subset of participants from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Participants  Ambulatory persons (n = 10 355), aged 55 years or older, with low-density lipoprotein cholesterol (LDL-C) of 120 to 189 mg/dL (100 to 129 mg/dL if known CHD) and triglycerides lower than 350 mg/dL, were randomized to pravastatin (n = 5170) or to usual care (n = 5185). Baseline mean total cholesterol was 224 mg/dL; LDL-C, 146 mg/dL; high-density lipoprotein cholesterol, 48 mg/dL; and triglycerides, 152 mg/dL. Mean age was 66 years, 49% were women, 38% black and 23% Hispanic, 14% had a history of CHD, and 35% had type 2 diabetes.

Intervention  Pravastatin, 40 mg/d, vs usual care.

Main Outcome Measures  The primary outcome was all-cause mortality, with follow-up for up to 8 years. Secondary outcomes included nonfatal myocardial infarction or fatal CHD (CHD events) combined, cause-specific mortality, and cancer.

Results  Mean follow-up was 4.8 years. During the trial, 32% of usual care participants with and 29% without CHD started taking lipid-lowering drugs. At year 4, total cholesterol levels were reduced by 17% with pravastatin vs 8% with usual care; among the random sample who had LDL-C levels assessed, levels were reduced by 28% with pravastatin vs 11% with usual care. All-cause mortality was similar for the 2 groups (relative risk [RR], 0.99; 95% confidence interval [CI], 0.89-1.11; P = .88), with 6-year mortality rates of 14.9% for pravastatin vs 15.3% with usual care. CHD event rates were not significantly different between the groups (RR, 0.91; 95% CI, 0.79-1.04; P = .16), with 6-year CHD event rates of 9.3% for pravastatin and 10.4% for usual care.

Conclusions  Pravastatin did not reduce either all-cause mortality or CHD significantly when compared with usual care in older participants with well-controlled hypertension and moderately elevated LDL-C. The results may be due to the modest differential in total cholesterol (9.6%) and LDL-C (16.7%) between pravastatin and usual care compared with prior statin trials supporting cardiovascular disease prevention.

ALLHAT Authors/Officers and Coordinators: Curt D. Furberg, MD, PhD; Jackson T. Wright, Jr, MD, PhD; Barry R. Davis, MD, PhD; Jeffrey A. Cutler, MD, MPH; Michael Alderman, MD; Henry Black, MD; William Cushman, MD; Richard Grimm, MD, PhD; L. Julian Haywood, MD; Frans Leenen, MD; Suzanne Oparil, MD; Jeffrey Probstfield, MD; Paul Whelton, MD, MSc; Chuke Nwachuku, MA, MPH; David Gordon, MD, PhD; Michael Proschan, PhD; Paula Einhorn, MD, MS; Charles E. Ford, PhD; Linda B. Piller, MD, MPH; J. Kay Dunn, PhD; David Goff, MD, PhD; Sara Pressel, MS; Judy Bettencourt, MPH; Barbara deLeon, BA; Lara M. Simpson, MS; Joe Blanton, MS; Therese Geraci, MSN, RN, CS; Sandra M. Walsh, RN; Christine Nelson, RN, BSN; Mahboob Rahman, MD; Anne Juratovac, RN; Robert Pospisil, RN; Lillian Carroll, RN; Sheila Sullivan, BA; Jeanne Russo, BSN; Gail Barone, RN; Rudy Christian, MPH; Sharon Feldman, MPH; Tracy Lucente, MPH; David Calhoun, MD; Kim Jenkins, MPH; Peggy McDowell, RN; Janice Johnson, BS; Connie Kingry, RN, BSN; Juan Alzate, MD; Karen L. Margolis, MD; Leslie Ann Holland-Klemme, BA; Brenda Jaeger; Jeffrey Williamson, MD, MHS; Gail Louis, RN; Pamela Ragusa, RN, BSN; Angela Williard, RN, BSN; R. L. Sue Ferguson, RN; Joanna Tanner; John Eckfeldt, MD, PhD; Richard Crow, MD; John Pelosi, RPh, MS.

RELATED LETTERS

Lipid-Lowering Therapy and Risk of Coronary Events
William C. Taylor
JAMA. 2003;289(16):2070.
EXTRACT | FULL TEXT  

Lipid-Lowering Therapy and Risk of Coronary Events
John A. Blakely
JAMA. 2003;289(16):2070-2071.
EXTRACT | FULL TEXT  

Lipid-Lowering Therapy and Risk of Coronary Events
Luca Mascitelli and Francesca Pezzetta
JAMA. 2003;289(16):2071.
EXTRACT | FULL TEXT  

Lipid-Lowering Therapy and Risk of Coronary Events
Claude K. Lardinois
JAMA. 2003;289(16):2071.
EXTRACT | FULL TEXT  

The Role of Statins in Primary Prevention of Cardiovascular Disease
Klaus Eichler, Milo A. Puhan, and Lucas M. Bachmann
Arch Intern Med. 2007;167(10):1100.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
JAMA. 2002;288(23):2981-2997.
ABSTRACT | FULL TEXT  

The ALLHAT Lipid Lowering Trial—Less Is Less
Richard C. Pasternak
JAMA. 2002;288(23):3042-3044.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Opportunities for Enhancing the FDA Guidance on Pharmacovigilance
Psaty and Vandenbroucke
JAMA 2008;300:952-954.
FULL TEXT  

Statins, Low-Density Lipoprotein Cholesterol, and Risk of Cancer
Alsheikh-Ali et al.
J Am Coll Cardiol 2008;0:j.jacc.2008.06.037v1-14098.
ABSTRACT | FULL TEXT  

The choice of antihypertensive therapy in patients with the metabolic syndrome--time to change recommendations?
Hilgers and Mann
Nephrol Dial Transplant 2008;0:gfn455v1-gfn455.
FULL TEXT  

Do People With Diabetes Need Statins?
White
The Diabetes Educator 2008;34:664-673.
ABSTRACT | FULL TEXT  

Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force
Norris et al.
ANN INTERN MED 2008;148:855-868.
ABSTRACT | FULL TEXT  

Effect of Pretreatment With Statins on Ischemic Stroke Outcomes
Reeves et al.
Stroke 2008;39:1779-1785.
ABSTRACT | FULL TEXT  

Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial
Howard et al.
JAMA 2008;299:1678-1689.
ABSTRACT | FULL TEXT  

Usefulness of Pravastatin in Primary Prevention of Cardiovascular Events in Women: Analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA Study)
Mizuno et al.
Circulation 2008;117:494-502.
ABSTRACT | FULL TEXT  

Generalizability of the Results of Randomized Trials
Weiss et al.
Arch Intern Med 2008;168:133-135.
FULL TEXT  

Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis.
Afilalo et al.
J Am Coll Cardiol 2008;51:37-45.
ABSTRACT | FULL TEXT  

Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort
Flick et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:2218-2225.
ABSTRACT | FULL TEXT  

Renin: friend or foe?
Brown
Heart 2007;93:1026-1033.
ABSTRACT | FULL TEXT  

Statins and the Risk of Colorectal Cancer: A Meta-Analysis of 18 Studies Involving More Than 1.5 Million Patients
Bonovas et al.
JCO 2007;25:3462-3468.
ABSTRACT | FULL TEXT  

Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus
Riche and McClendon
Am J Health Syst Pharm 2007;64:1603-1610.
ABSTRACT | FULL TEXT  

Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials
Alsheikh-Ali et al.
J Am Coll Cardiol 2007;50:409-418.
ABSTRACT | FULL TEXT  

Cerebral Vascular Dysfunction During Hypercholesterolemia
Kitayama et al.
Stroke 2007;38:2136-2141.
ABSTRACT | FULL TEXT  

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members: et al.
Eur Heart J 2007;0:ehm236v1-75.
FULL TEXT  

The Role of Statins in Primary Prevention of Cardiovascular Disease
Eichler et al.
Arch Intern Med 2007;167:1100-1100.
FULL TEXT  

Lipid-Lowering Therapy and Outcomes in Heart Failure
Ray et al.
J CARDIOVASC PHARMACOL THER 2007;12:27-35.
ABSTRACT  

Does pravastatin promote cancer in elderly patients? A meta-analysis
Bonovas and Sitaras
CMAJ 2007;176:649-654.
ABSTRACT | FULL TEXT  

Coronary Heart Disease in Patients With Diabetes: Part I: Recent Advances in Prevention and Noninvasive Management
Berry et al.
J Am Coll Cardiol 2007;49:631-642.
ABSTRACT | FULL TEXT  

Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly?
Robinson et al.
Stroke 2007;38:441-450.
ABSTRACT | FULL TEXT  

The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease)
Dzau et al.
Circulation 2006;114:2850-2870.
FULL TEXT  

The Effect of Modifiable Risk Factors on Pancreatic Cancer Mortality in Populations of the Asia-Pacific Region
Ansary-Moghaddam et al.
Cancer Epidemiol. Biomarkers Prev. 2006;15:2435-2440.
ABSTRACT | FULL TEXT  

Statin Therapy after Stroke or Transient Ischemic Attack
Cohen et al.
NEJM 2006;355:2368-2371.
FULL TEXT  

Primary Prevention of Cardiovascular Diseases With Statin Therapy: A Meta-analysis of Randomized Controlled Trials
Thavendiranathan et al.
Arch Intern Med 2006;166:2307-2313.
ABSTRACT | FULL TEXT  

Multitherapy for diabetes.
Vos
CMAJ 2006;175:1246-1247.
FULL TEXT  

Statins, Fibrates, and Melanoma Risk: a Systematic Review and Meta-analysis.
Freeman et al.
JNCI J Natl Cancer Inst 2006;98:1538-1546.
ABSTRACT | FULL TEXT  

Analysis of Efficacy and Safety in Patients Aged 65-75 Years at Randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
Neil et al.
Diabetes Care 2006;29:2378-2384.
ABSTRACT | FULL TEXT  

Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials
Bonovas et al.
JCO 2006;24:4808-4817.
ABSTRACT | FULL TEXT  

The Argument Against the Appropriateness of Over-the-Counter Statins
Barter and Rye
Circulation 2006;114:1315-1320.
FULL TEXT  

Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease
Molitch
CJASN 2006;1:1090-1099.
ABSTRACT | FULL TEXT  

Statins for primary prevention in type 2 diabetes
DTB 2006;44:57-60.
ABSTRACT | FULL TEXT  

Statins in the treatment of chronic heart failure: Biological and clinical considerations
van der Harst et al.
Cardiovasc Res 2006;71:443-454.
ABSTRACT | FULL TEXT  

A 39-year-old woman with hypercholesterolemia.
Mittleman
JAMA 2006;296:319-326.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)
Knopp et al.
Diabetes Care 2006;29:1478-1485.
ABSTRACT | FULL TEXT  

Statins and the Risk of Cancer
Freeman et al.
JAMA 2006;295:2720-2721.
FULL TEXT  

Intensive Statin Therapy and the Risk of Hospitalization for Heart Failure After an Acute Coronary Syndrome in the PROVE IT-TIMI 22 Study
Scirica et al.
J Am Coll Cardiol 2006;47:2326-2331.
ABSTRACT | FULL TEXT  

Statin-Induced Myopathy: The Two Faces of Janus
Arora et al.
J CARDIOVASC PHARMACOL THER 2006;11:105-112.
ABSTRACT  

Effects of Bezafibrate on HDL2/HDL3 Ratio in Postmenopausal Hypertriglyceridemic Women
Ushiroyama et al.
J CARDIOVASC PHARMACOL THER 2006;11:142-148.
ABSTRACT  

Assessment of Patients' and Physicians' Compliance to an ACE Inhibitor Treatment Based on Urinary N-Acetyl Ser-Asp-Lys-Pro Determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) Study.
Azizi et al.
Diabetes Care 2006;29:1331-1336.
ABSTRACT | FULL TEXT  

Statin use and breast cancer: prospective results from the Women's Health Initiative.
Cauley et al.
JNCI J Natl Cancer Inst 2006;98:700-707.
ABSTRACT | FULL TEXT  

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute
Smith et al.
J Am Coll Cardiol 2006;47:2130-2139.
FULL TEXT  

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute
Smith et al.
Circulation 2006;113:2363-2372.
FULL TEXT  

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials
Costa et al.
BMJ 2006;332:1115-1124.
ABSTRACT | FULL TEXT  

Introduction: Pharmacotherapy for Dyslipidemia
Dumo
Journal of Pharmacy Practice 2006;19:61-62.
 

What's New? Guidelines and Goals
Wigle and Birtcher
Journal of Pharmacy Practice 2006;19:103-112.
ABSTRACT  

Value of Noninvasive Hemodynamics to Achieve Blood Pressure Control in Hypertensive Subjects
Smith et al.
Hypertension 2006;47:771-777.
ABSTRACT | FULL TEXT  

Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia
Jenkins et al.
Am. J. Clin. Nutr. 2006;83:582-591.
ABSTRACT | FULL TEXT  

REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia
Ginsberg
J. Clin. Endocrinol. Metab. 2006;91:383-392.
ABSTRACT | FULL TEXT  

Stats on Statins: Anything but Static
McLaughlin
JNCI J Natl Cancer Inst 2006;98:4-5.
FULL TEXT  

Cholesterol-Lowering Drugs and Colorectal Cancer Incidence in a Large United States Cohort
Jacobs et al.
JNCI J Natl Cancer Inst 2006;98:69-72.
ABSTRACT | FULL TEXT  

Statins and Cancer Risk: A Meta-analysis
Dale et al.
JAMA 2006;295:74-80.
ABSTRACT | FULL TEXT  

Lipid Management in Type 2 Diabetes
Solano and Goldberg
Clin. Diabetes 2006;24:27-32.
ABSTRACT | FULL TEXT  

Quality Assessment of Dyslipidemia in Managed Care: Current Best Evidence Should Be Used to Benchmark Quality
Nair and Saseen
The Annals of Pharmacotherapy 2006;40:124-127.
ABSTRACT | FULL TEXT  

The Role of Statins in Cancer Therapy.
Hindler et al.
The Oncologist 2006;11:306-315.
ABSTRACT | FULL TEXT  

Use of Statins and Breast Cancer: A Meta-Analysis of Seven Randomized Clinical Trials and Nine Observational Studies
Bonovas et al.
JCO 2005;23:8606-8612.
ABSTRACT | FULL TEXT  

JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Prepared by: British Cardiac Society, British Hype
Heart 2005;91:v1-v52.
FULL TEXT  

Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?: A Meta-Regression Analysis
Robinson et al.
J Am Coll Cardiol 2005;46:1855-1862.
ABSTRACT | FULL TEXT  

Managing Abnormal Blood Lipids: A Collaborative Approach
Fletcher et al.
Circulation 2005;112:3184-3209.
ABSTRACT | FULL TEXT  

Statins and Cancer Development
Duncan et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:1897-1898.
ABSTRACT | FULL TEXT  

The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient
Ong
QJM 2005;98:599-614.
ABSTRACT | FULL TEXT  

Should Diabetes Be Considered a Coronary Heart Disease Risk Equivalent?: Results from 25 years of follow-up in the Renfrew and Paisley Survey
Whiteley et al.
Diabetes Care 2005;28:1588-1593.
ABSTRACT | FULL TEXT  

The realities of dyslipidaemia: what do the studies tell us?
Kastelein
Eur Heart J Suppl 2005;7:F27-F33.
ABSTRACT | FULL TEXT  

Over-the-Counter Statins
Choudhry and Avorn
ANN INTERN MED 2005;142:910-913.
ABSTRACT | FULL TEXT  

Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts
Di Napoli et al.
Cardiovasc Res 2005;66:462-471.
ABSTRACT | FULL TEXT  

The cost of glucocorticoid-associated adverse events in rheumatoid arthritis
Pisu et al.
Rheumatology (Oxford) 2005;44:781-788.
ABSTRACT | FULL TEXT  

Hypertension Management in the Elderly Has Improved: Ontario Prescribing Trends, 1994 to 2002
Tu et al.
Hypertension 2005;45:1113-1118.
ABSTRACT | FULL TEXT  

Statins and the Risk of Colorectal Cancer
Poynter et al.
NEJM 2005;352:2184-2192.
ABSTRACT | FULL TEXT  

Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy
Chapman et al.
Arch Intern Med 2005;165:1147-1152.
ABSTRACT | FULL TEXT  

Secondary prevention of heart disease with statins: Groups were as different as chalk and cheese
Penston
BMJ 2005;330:1208-1208.
FULL TEXT  

Hyperlipidemia in Seniors: Too Much, Too Little, Too Late?
Hirth
J. Gerontol. A Biol. Sci. Med. Sci. 2005;60:595-597.
FULL TEXT  

The Challenge of Achieving National Cholesterol Goals in Patients With Diabetes
Kennedy et al.
Diabetes Care 2005;28:1029-1034.
ABSTRACT | FULL TEXT  

Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA)
Sever et al.
Diabetes Care 2005;28:1151-1157.
ABSTRACT | FULL TEXT  

Simvastatin over the counter
DTB 2005;43:25-28.
ABSTRACT | FULL TEXT  

Review: Defining the role of statins in diabetes
Tuomilehto and Leiter
British Journal of Diabetes & Vascular Disease 2005;5:55-62.
ABSTRACT  

Modern intervention strategies for managing dyslipidaemia: the case for combination therapy
Drexel
British Journal of Diabetes & Vascular Disease 2005;5:S17-S23.
ABSTRACT  

Two-Year Statin Therapy Does Not Alter the Progression of Intima-Media Thickness in Patients With Type 2 Diabetes Without Manifest Cardiovascular Disease
Beishuizen et al.
Diabetes Care 2004;27:2887-2892.
ABSTRACT | FULL TEXT  

Implications of recent end-point trials on future management of hypertension and dyslipidaemia
Dahlof
Eur Heart J Suppl 2004;6:G13-G17.
ABSTRACT | FULL TEXT  

Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis
Amarenco et al.
Stroke 2004;35:2902-2909.
ABSTRACT | FULL TEXT  

Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure: The CAMELOT Study: A Randomized Controlled Trial
Nissen et al.
JAMA 2004;292:2217-2225.
ABSTRACT | FULL TEXT  

Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis
Brown et al.
CMAJ 2004;171:1189-1192.
ABSTRACT | FULL TEXT  

Should a statin be routinely prescribed for primary prevention of cardiovascular disease in diabetes mellitus?
Hackam
CMAJ 2004;171:857-857.
FULL TEXT  

The case for statins: has it really been made?
Thompson and Temple
JRSM 2004;97:461-464.
FULL TEXT  

Therapeutic options for patients with chronic myocardial ischaemia
Serruys and Aoki
Eur Heart J Suppl 2004;6:E2-E11.
ABSTRACT | FULL TEXT  

Update on Statins: 2003
Vaughan and Gotto
Circulation 2004;110:886-892.
FULL TEXT  

Mevalonate Promotes the Growth of Tumors Derived from Human Cancer Cells in Vivo and Stimulates Proliferation in Vitro with Enhanced Cyclin-dependent Kinase-2 Activity
Duncan et al.
J. Biol. Chem. 2004;279:33079-33084.
ABSTRACT | FULL TEXT  

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy et al.
J Am Coll Cardiol 2004;44:720-732.
ABSTRACT | FULL TEXT  

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy et al.
Arterioscler. Thromb. Vasc. Bio. 2004;24:e149-e161.
ABSTRACT | FULL TEXT  

Management of dyslipidaemia
Thompson
Heart 2004;90:949-955.
FULL TEXT  

Perspective on Selected Issues in Cardiovascular Disease Research With a Focus on Black Americans
Albert et al.
Circulation 2004;110:e7-e12.
FULL TEXT  

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy et al.
Circulation 2004;110:227-239.
ABSTRACT | FULL TEXT  

Effectiveness of Statin Therapy in Adults With Coronary Heart Disease
Wilt et al.
Arch Intern Med 2004;164:1427-1436.
ABSTRACT | FULL TEXT